Dextromethorphan and guaifenesin use should be monitored cautiously in patients with "poor metabolizer" CYP2D6 enzyme concentrations and people that are sedated. This mixture medication includes a huge median toxic dose (TD50) to median productive dose (ED50) ratio (or therapeutic index) in these individuals. To overview: Medical investigations according to MDR https://donovanydgij.topbloghub.com/36434832/everything-about-dextromethorphan-dxm-for-sale-in-usa